LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...

Backed by a meta-analysis of over 4,300 patients, once-weekly tirzepatide slashes blood sugar, weight, and cardiovascular risks more effectively than daily insulin, offering a groundbreaking ...

Utah-based Civica will begin selling a type of long-acting insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s Petersburg facility. Civica announced Thursday it has ...

HHS officials are moving forward with a plan to produce 4.8 million doses of H5N1 avian flu vaccine; Novo Nordisk’s long-acting insulin had a greater risk of excessively lowering patients’ blood sugar ...

The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...

On May 24, an FDA advisory committee will meet to discuss the safety profile of Awiqli (insulin icodec), Novo Nordisk’s long-lasting insulin, after a study showed the drug poses an increased risk of ...

While it’s not injected as frequently as short-acting insulin, which is taken with meals, it still needs to be taken at least once a day. Now, the effectiveness of a novel basal insulin, efsitora alfa ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order, and ...

Adults with type 1 or type 2 diabetes who used a continuous glucose monitor experienced fewer emergency department and ...

Intensive therapy should achieve glycemic control while avoiding severe and nocturnal hypoglycemia as much as possible. Physiologic, behavioral, and pharmacologic factors contribute to nocturnal ...

Three U.S. Senators say they are "alarmed" Novo Nordisk discontinued U.S. sales of a popular insulin brand and are demanding answers from the pharmaceutical giant they say left patients without an ...